1 World Health Organisation (WHO). WHO European Regional Obesity Report 2022.
https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf (abgerufen am 01.03.2023).
2 Berrington de Gonzalez A, Hartge P, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010 Dec 2;363(23):2211-9.
3 Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 Mar 28;373(9669):1083-96.
4 Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 May;15(5):288-298.
5 Timper K, Brüning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017 Jun 1;10(6):679-689.
6 Sharma AM, Bélanger A, et al. Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study. Clin Obes. 2019 Oct;9(5):e12329.
7 Puhl RM, Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. Obesity (Silver Spring). 2006 Oct;14(10):1802-15.
8 Himmelstein MS, Puhl RM, Quinn DM. Intersectionality: An Understudied Framework for Addressing Weight Stigma. Am J Prev Med. 2017 Oct;53(4):421-431.
9 Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obes Rev. 2018 Aug;19(8):1141-1163.
10 Himmelstein MS, Puhl RM, Pearl RL, Pinto AM, Foster GD. Coping with Weight Stigma Among Adults in a Commercial Weight Management Sample. Int J Behav Med. 2020 Oct;27(5):576-590.
11 Puhl RM, Lessard LM, Himmelstein MS, Foster GD. The roles of experienced and internalized weight stigma in healthcare experiences: Perspectives of adults engaged in weight management across six countries. PLoS One. 2021 Jun 1;16(6):e0251566.
12 Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 2022 Jan;33(1):18-35.
13 Schweizerische Adipositas-Stiftung SAPS. Schweizer Praxisleitfaden Adipositas 2016.
https://saps.ch/de/home/paxisleitfaden-adipositas-2016 (abgerufen am 01.03.2023).
14 The European Association für the Study of Obesity. Guidelines.
https://easo.org/education/guidelines (abgerufen am 01.03.2023).
15 Canadian Adult Obesity Clinical Practice Guidelines (CPGs).
https://obesitycanada.ca/guidelines/ (abgerufen am 01.03.2023).
16 Fujioka K, O‘Neil PM, Davies M, et al. Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers. Obesity (Silver Spring). 2016 Nov;24(11):2278-2288.
17 le Roux CW, Astrup A, et al. SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017 Apr 8;389(10077):1399-1409.
18 Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756.
19 Peterli R, Wölnerhanssen BK, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA. 2018 Jan 16;319(3):255-265.
20 Syn NL, Cummings DE, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021 May 15;397(10287):1830-1841.
21 Wilding JPH, Batterham RL, et al. STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.
22 Jastreboff AM, Aronne LJ, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216.
23 Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022 Mar;21(3):201-223.